Evidence map›Paper›PMID 33309392›Full record

SynthesisBlood reviews2021

The impact of ABO blood group on COVID-19 infection risk and mortality: A systematic review and meta-analysis.

Nanyang Liu, Tingting Zhang, Lina Ma, Huiqing Zhang, Huichan Wang, Wei Wei, Hui Pei, Hao Li

Open access · hybridAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Blood reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed, 4 pooled it
17.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 4 syntheses or guidelines pooled it, 184 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Systematic review and meta-analysis of the susceptibility of ABO blood group to COVID-19 infection.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2021
    Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Nanyang LiuXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Tingting ZhangCollege of First Clinical Medicine, Shandong University of Traditional Chinese Medicine, China.
Lina MaXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Huiqing ZhangXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Huichan WangXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Wei WeiCollege of First Clinical Medicine, Shandong University of Traditional Chinese Medicine, China.
Hui PeiXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Hao LiXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China. Electronic address: xyhplihao1965@126.com.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNXiyuan Hospital · CNShandong University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 2019 coronavirus disease (COVID-19) has become a global pandemic. Several studies report that ABO blood group polymorphism may be related to COVID-19 susceptibility and clinical outcomes; however, the results are controversial. We conducted a systematic review and meta-analysis to investigate whether ABO blood groups are associated with increased COVID-19 morbidity and mortality. A total of 715 articles were retrieved from seven databases. Ten articles were selected for meta-analysis after removal of duplicates and two levels of screenings. Overall, individuals with blood group A [odds ratio (OR) = 1.33, 95% confidence interval (CI) 1.14 to 1.56] and B (OR = 1.06, 95% CI 1.00 to 1.13) had a substantially higher risk of COVID-19, whereas this was not the case for blood group AB (OR = 1.07, 95% CI 0.88 to 1.30). Individuals with blood group O was not prone to develop the disease (OR = 0.71, 95% CI 0.60 to 0.84). Moreover, the risk of COVID-19 was significantly associated with the Rh-positive blood group (OR = 1.22, 95% CI 0.99 to 1.50). A meta-analysis of 5 studies suggested that blood group A was associated with a significantly increased risk of COVID-19 mortality (OR = 1.25, 95% CI 1.02 to 1.52). Mild publication bias was found in the included studies. This systematic review and meta-analysis indicated that blood groups A and B may be risk factors for COVID-19, whereas the blood group O appears to be protective. Blood group A may be related to unfavourable outcomes. Further rigorous and high-quality research evidence is needed to confirm this association.

Indexed as

PandemicsSARS-CoV-2ABO Blood-Group SystemCase-Control StudiesCOVID-19Genetic Predisposition to DiseaseHumansOdds RatioRetrospective StudiesRh-Hr Blood-Group SystemRiskSurvival AnalysisABO Blood-Group SystemRh-Hr Blood-Group System2019 coronavirus diseaseABO blood groupAnti-A antibodyVirus

Identifiers

PMID33309392
PMCPMC7834371
OpenAlexW3113144109

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.